XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues $ 180,556 $ 120,129 $ 466,290 $ 363,964
Finished Pharmaceutical Products Segment        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 176,366 117,120 455,242 353,789
Finished Pharmaceutical Products Segment | Glucagon        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 29,514 14,224 82,486 37,003
Finished Pharmaceutical Products Segment | Primatene Mist        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 24,834 18,359 64,837 62,030
Finished Pharmaceutical Products Segment | Epinephrine        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 20,199 19,502 57,004 52,777
Finished Pharmaceutical Products Segment | Lidocaine        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 15,522 12,621 43,174 39,253
Finished Pharmaceutical Products Segment | Phytonadione        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 7,449 13,978 33,017 37,834
Finished Pharmaceutical Products Segment | Enoxaparin        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 7,702 7,983 25,441 27,138
Finished Pharmaceutical Products Segment | Naloxone        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 4,715 6,818 14,774 21,424
Finished Pharmaceutical Products Segment | Other Finished Pharmaceutical Products        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 37,730 23,635 105,808 76,330
Finished Pharmaceutical Products Segment | Total finished pharmaceutical products net revenues        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues 147,665 $ 117,120 426,541 $ 353,789
Finished Pharmaceutical Products Segment | BAQSIMI        
Segment Reporting Information, Revenue for Reportable Segment [Abstract]        
Total net revenues $ 28,701   $ 28,701